Wang Nana, Cao Shuming, Tan Xiaofeng, Liu Meirong
Department of General Internal Medicine, Tianjin Hospital, Tianjin, China.
Department of Hand Surgery, Tianjin Hospital, Tianjin, China.
Front Pharmacol. 2025 Feb 25;16:1540636. doi: 10.3389/fphar.2025.1540636. eCollection 2025.
is expressed in various tumors and leukemia cell lines. This study aims to explore the effect of in lung adenocarcinoma (LUAD).
The data on LUAD patients were collected from the Cancer Genome Atlas and Gene Expression Omnibus database. The expression of in LUAD and LUAD cell lines was analyzed via differential gene analysis, qRT-PCR assay, and Western blotting assay. The correlation of expression with the onset of LUAD were calculated using Pearson correlation analysis. The transcription factors correlated with expression were screened by differential expression analysis and Pearson correlation analysis. Moreover, the effect of on the immune landscape of LUAD was analyzed using CIBERSORT algorithm. The GDSC and CTRP databases were used to analyze the drug sensitivity of hub gene.
was highly expressed in LUAD patients and cells, and expression was correlated with metastasis, pathological stages, and age of LUAD patients. The transcription factors E2F1 and E2F3 could regulate expression by binding upstream of . The 8 immune cell infiltration levels were differential between and patients. The ESTIMATEScore and ImmuneScore levels were decreased, the TumorPurity level was elevated, and 6 immune checkpoint expressions were increased in LRFN4 patients. Moreover, LRFN4 patients had inferior prognosis. The mutation rate of TP53, TTN, and MUC6 and the level of TMB were increased in patients. The expressions of TCF3, E2F1, E2F3, and were correlated with the IC50 of multiple drugs.
may serve as a novel prognostic biomarker for LUAD, shows specific overexpression in LUAD and may be a potential therapeutic target for LUAD patients.
在多种肿瘤和白血病细胞系中表达。本研究旨在探讨其在肺腺癌(LUAD)中的作用。
从癌症基因组图谱和基因表达综合数据库收集LUAD患者的数据。通过差异基因分析、qRT-PCR检测和蛋白质免疫印迹分析,分析其在LUAD及LUAD细胞系中的表达。采用Pearson相关分析计算其表达与LUAD发病的相关性。通过差异表达分析和Pearson相关分析筛选与其表达相关的转录因子。此外,使用CIBERSORT算法分析其对LUAD免疫格局的影响。利用GDSC和CTRP数据库分析枢纽基因的药物敏感性。
其在LUAD患者和细胞中高表达,且其表达与LUAD患者的转移、病理分期和年龄相关。转录因子E2F1和E2F3可通过结合其上游来调节其表达。其高表达组和低表达组患者的8种免疫细胞浸润水平存在差异。LRFN4高表达患者的ESTIMATEScore和ImmuneScore水平降低,TumorPurity水平升高,6种免疫检查点表达增加。此外,LRFN4高表达患者预后较差。其高表达患者中TP53、TTN和MUC6的突变率及肿瘤突变负荷(TMB)水平升高。TCF3、E2F1、E2F3和其表达与多种药物的半数抑制浓度(IC50)相关。
其可能作为LUAD的一种新型预后生物标志物,在LUAD中表现出特异性过表达,可能是LUAD患者的潜在治疗靶点。